LBA40 Primary results from the phase III ALTN-AK105-III-02 study: Anlotinib plus penpulimab versus sorafenib as first-line (1L) therapy for advanced hepatocellular carcinoma (aHCC)

作者：Jin Zhou, Jie Fan, Shunchang Jiao, Li Bai, Jia Luo, Yuezong Bai, Yueyin Pan, Yuzhen Gao, Rui Shi, William Zhang, Jie Zheng, Xing Hua, Aibing Xu, Shaofan Hu, Da Miao, Ruimin Wang, Junjie Ma, Wei-Hua Jia, Wenjuan Wu, Cong Peng · 发表于：Annals of Oncology · 年份：2024 · DOI：10.1016/j.annonc.2024.08.2280 · 被引用次数：10 · 研究领域：Lung Cancer Research Studies、Cancer, Hypoxia, and Metabolism、Medical Imaging Techniques and Applications